Spectrum Therapeutics Partners with Emerald Clinics on Real World Evidence Research
Spectrum Therapeutics ("Spectrum"), the medical division of Canopy Growth Corporation (Canopy Growth), is pleased to announce an Australian first for the company. Spectrum has partnered with Emerald Clinics Australia (Emerald Clinics) to collect real world data on the safety and effectiveness of Spectrum Therapeutics' medical cannabis products.
Under the terms of the agreement, following ethics approval, Emerald Clinics will collect clinical outcome data for up to 500 patients prescribed Spectrum Therapeutics products in Australia throughout the course of their treatment. The study, which will take place over the next 12 months, will enable Spectrum Therapeutics to better understand the safety and effectiveness of its products when used in a supervised and regulated clinical setting.
"Spectrum Therapeutics is committed to investing in ongoing local research, while making sure that quality and regulated supply of medical cannabis is accessible to patients in Australia, and this project will allow us to do both," says Dr Christina Xinos, Medical Director at Spectrum Therapeutics. "This partnership allows us to work with Emerald Clinic's innovative care model which ensures that patients receive extensive follow up and support throughout their treatment while collecting real world data which will complement the robust clinical trials required to get our products registered with the Therapeutic Goods Administration."
"Australia's regulatory system enables the collection of high quality data due to the stringent product quality controls in place, and along with the requirement for detailed monitoring plans, this allows us to work towards a more evidence based approach to prescribing cannabinoid medicines," says Dr Alistair Vickery, Principal Investigator and Medical Director at Emerald Clinics.
Spectrum Therapeutics' research program is committed to furthering the science of cannabis through clinical trials and real world evidence approaches, with a focus on conditions with high unmet medical needs, particularly around the areas of chronic pain, anxiety disorders and insomnia.
Today's announcement is the first in a series of research initiatives that Spectrum Therapeutics is delivering locally, aligned with its commitment to invest in ongoing global research, including:
- 24 therapeutic trials planned and ongoing;
- 26 third party preclinical and clinical studies planned and ongoing;
- 1000+ patients participating in human health clinical trials; and
- A unique global pharmacovigilance programme
About Emerald Clinics
Emerald Clinics is a healthcare technology and services company incorporated in March 2018 whose mission is to improve lives, by learning from the experience of every patient that is treated with a cannabinoid medicine. Our team includes specialist physicians, experienced General Practitioners and clinical trials experts to deliver best-practice care for patients who have exhausted conventional therapies in Australia through our clinics in Sydney, Melbourne, Perth and Northern NSW.
About Canopy Growth Corporation
Canopy Growth (TSX: WEED, NYSE: CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through the Company's subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. The Company has operations in over a dozen countries across five continents. The Company's medical division, Spectrum Therapeutics, is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and has devoted millions of dollars toward cutting edge, commercialisable research and IP development.
Spectrum Therapeutics sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol under the brand Bionorica Ethics. The Company operates retail stores across Canada under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognised cannabis brand which has built a large and loyal following by focusing on quality products and meaningful customer relationships. From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates eleven licensed cannabis production sites with over 4.7 million square feet of production capacity, including over one million square feet of GMP certified production space. For more information visit www.canopygrowth.com
About Spectrum Therapeutics
Spectrum Therapeutics, the medical division of Canopy Growth Corporation (TSX: WEED, NYSE: CGC), is dedicated to educating healthcare practitioners, furthering the public's understanding of medical cannabis and its various applications, and cutting edge, commercialisable research and IP development. Founded in Canada, Spectrum Therapeutics operates in Australia, South America, Africa and across Europe. Its products are available in a wide range of potencies and formats designed to simplify the dialogue around strength and dosage by applying a colour-coded spectrum to categorise medical cannabis according to THC and CBD levels.
Spectrum Therapeutics' offerings include whole flower cannabis, oils and new innovations such as Softgels in addition to single cannabinoid medicine Dronabinol under the brand Bionorica Ethics. Through product simplification, robust clinical research and ongoing education of healthcare professionals, Spectrum Therapeutics is committed to addressing the unmet medical needs of patients around the globe.
 Only patients who have given full consent will be included in this study
For further information: Contact:, Spectrum Therapeutics Australia, Ben Quirin, Regional Managing Director, APAC, email@example.com, +61 466 231 441; Emerald Clinics, Adam James, Media Relations, firstname.lastname@example.org, +61 400 105 462